Barbara Ann Burtness, MD
Professor of Medicine (Medical Oncology)
Disease Aligned Research Team Leader, Head and Neck Cancers Program
Co-Director, Developmental Therapeutics Research Program
Yale University School of Medicine and Yale Cancer Center
New Haven, CT
This activity will cover the treatment and management of patients with squamous cell carcinoma of the head and neck (SCCHN).
After completing the CME activity, learners should be better able to:
- Evaluate clinical trial data on the use of biomarkers to predict response to immunotherapy in head and neck squamous cell carcinoma (SCCHN)
- Utilize current treatment guidelines and clinical trial data to appropriately sequence and combine therapies in the management of SCCHN
- Develop strategies to identify and manage immune-related adverse events associated with immune checkpoint inhibitors
This activity is designed to meet the educational needs of medical oncologists, surgical oncologists, and other healthcare professionals who manage patients with head and neck squamous cell carcinoma.
ACCREDITATION AND DESIGNATION STATEMENTS
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Med Learning Group designates this web-based live activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the web-based live activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with head and neck cancer.
Credits: 1.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Burtness discloses that she has received consulting fees from Aduro, Alligator Biosciences, Celgene, CUE Biopharma, Debiopharm, Glaxo SmithKline, IDDI, Maverick Therapeutics, Merck & Co., Inc., Nanobiotix and Rakuten.
The independent reviewers, staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this web-based live activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the web-based live activity.
- Complete and submit the evaluation form.
You will receive your certificate after completion of the web-based live activity.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
RELEASE DATE: August 31, 2020
EXPIRATION DATE: August 31, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.